<unk> of <unk> <unk> <unk> administration for patients with patients with <unk> <unk> <unk> ( <unk> <unk> ) is <unk> .
<unk> <unk> <unk>
information <unk> <unk> <unk>
do not exclude the <unk> with any other <unk> .
2 <unk> <unk> <unk> <unk> : + <unk> 2 <unk> <unk>
16 .
always <unk> the <unk> shown by your doctor .
27 %
<unk> <unk> <unk> <unk> <unk> <unk> <unk> , Germany
this is at the rate of <unk> around 40 % of the <unk> <unk> in the past <unk> studies in which the <unk> had been carried out after the treatment of <unk> .
since then , the national authorities have known to work together and to <unk> their resources and their expertise .
<unk> <unk> ( <unk> )
15 .
- <unk> is not completely closed when the triangle on the <unk> of <unk> <unk>
the adverse effects of the <unk> <unk> in the <unk> and the <unk> are <unk> ( COM ( 2 ) and the <unk> of <unk> ( <unk> % ) and <unk> ( <unk> % ) .
<unk> : in a study study in a study of <unk> <unk> <unk> children and <unk> <unk> <unk> of 6 to 16 years , the adverse effects related to the treatment of <unk> during the age period of 3 weeks have been <unk> ( <unk> % ) , <unk> ( <unk> % ) , <unk> ( <unk> % ) .
in the event of <unk> treatment , a maximum period of 7 days of treatment is sufficient .
oral use
<unk> product subject to medical <unk> .
special number ( <unk> ) <unk> <unk> <unk> <unk>
<unk> <unk>
never <unk> the <unk> of any other <unk> .
Netherlands Netherlands
<unk> )
the study of digital <unk> has included the + + + , whereas the study carried out by the <unk> study has been <unk> and <unk> + + .
- <unk> ( <unk> for <unk> ) , <unk>
name OF <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>
<unk> OF <unk> <unk>
2 .
a <unk> <unk> may be resolved by the <unk> administration or <unk> <unk> of <unk> <unk> with <unk> of <unk> when patients are sufficient enough .
1 ( <unk> % )
solution for <unk> and <unk> .
<unk> OF <unk>
the response of each person at the expense of <unk> may <unk> , with different levels of <unk> <unk> and different <unk> .
<unk> <unk> <unk> <unk> , <unk> : + <unk> : + <unk> : + <unk> : +
the project provides for a system of information which is designed to develop an information system and then <unk> the electronic exchange of information between <unk> and <unk> , and the <unk> of this approach in the course of the information process .
the average average for treatment of this population was to 50 weeks .
however , it is <unk> to <unk> <unk> at least before or three hours after taking <unk> in order to limit the impact on <unk> <unk> .
in the course of use : do not use <unk> .
after having achieved this very maximum , the voluntary concentration <unk> quickly and the <unk> is <unk> in 4 to 6 hours .
detailed information on this <unk> is available on the Internet website of the European <unk> Agency ( <unk> ) <unk> : / <unk> / <unk> <unk> <unk> <unk>
all the patients by the <unk> <unk> <unk> must have a <unk> of <unk> <unk> ( for example , 200 <unk> / <unk> / <unk> , for example , of the treatment by <unk> <unk> <unk> .
<unk> / <unk> use : use within 6 weeks
<unk> <unk> <unk> <unk> <unk> , 8 <unk> <unk> <unk> : + <unk> <unk> : + <unk> <unk> : + <unk>
of 3 , 4 , 4 , 5 , 5 , 10 <unk> of 3 <unk> are available .
<unk> of <unk>
7 % <unk> <unk> 23 % <unk> 23 % <unk> <unk> <unk> <unk>
the reduction in the risk of the risk of the most important deficit has been found in the <unk> at the very high risk of <unk> such as <unk> <unk> and <unk> with a <unk> <unk> - 3 to <unk> .
<unk> in <unk> .
<unk> has been made technical in public health in the French <unk> of <unk> <unk> to health and <unk> <unk> .
<unk> the <unk> for oral administration in the <unk> of <unk> and put the <unk> on the basis of language .
<unk> <unk> <unk>
you have to ask your doctor about your ability to drive whether :
its active principle is <unk> human <unk> .
when you inject a <unk> in your <unk> , he is <unk> and the <unk> is <unk> by the <unk> of your <unk> and the <unk> <unk> .
in the formal administration , a reduction of the dose has been required in 75 % of patients .
one <unk> and a <unk> may occur during the treatment by <unk> / <unk> .
however , <unk> has been involved without any problem of <unk> other <unk> such as <unk> , <unk> <unk> <unk> and <unk> <unk> .
<unk> <unk>
<unk> of 3 or 4 % have been considered in 4 % of patients .
<unk> 30 <unk> <unk> are <unk> and <unk> <unk> <unk> <unk> <unk> and the Jewish code <unk> <unk> .
( heckling from 95 % )
further information
<unk> of the <unk> <unk> , <unk> <unk> , <unk> , <unk> , <unk>
<unk> <unk> <unk> <unk> <unk> <unk> , <unk> <unk> <unk> <unk> <unk> <unk> : + 36 1 <unk> <unk> <unk> : + <unk> ( 0 ) 2 <unk>
10 .
any product is being used or <unk> in accordance with the regulations .
<unk> / <unk> / <unk>
in the short part of the <unk> <unk> .
all the patients in <unk> or by <unk> have been presented in a <unk> event , which had a <unk> effect .
<unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>
5 .
this <unk> makes it possible to ensure that after dilution of <unk> <unk> <unk> the <unk> of <unk> <unk> <unk> contains 10 <unk> / <unk> of 2 <unk> / <unk> , which <unk> the amount of 20 <unk> by <unk> .
<unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>
name of <unk>
there are many medicines on <unk> <unk> in your body and can have a impact on your <unk> <unk> .
<unk> in a <unk> <unk> <unk> the risk of <unk> <unk> <unk> .
in the event of <unk> or <unk> , the solution must not be used .
3 .
88 <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>
<unk> are very often affected by the use of <unk> .
<unk> of <unk>
<unk> and <unk> <unk> <unk> ( too many <unk> in the site ) that you have not sufficiently <unk> .
<unk> knowledge :
<unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>
<unk> administration of <unk> <unk> <unk> , for example <unk> and <unk> , risk of the distribution of <unk> and / or its elimination .
<unk> <unk>
the patients that the <unk> control is significantly improved , for example in the context of <unk> <unk> , may have a change of warning signs of <unk> <unk> and must therefore be <unk> .
the <unk> of the <unk> application for the market has accepted the recommendations of <unk> , but it has been said that the <unk> on <unk> <unk> should be <unk> , because it is independent of <unk> <unk> .
failure to <unk> <unk> adjustment is necessary in the event of <unk> <unk> <unk> <unk> <unk> ( <unk> of <unk> <unk> and 80 <unk> / <unk> ) .
the training of <unk> has been <unk> in some animals after a relatively long time of <unk> <unk> , which , in a relatively long time , the changes of the <unk> have been <unk> .
- if you have a bad function of <unk> or <unk>
8 .
the <unk> used for <unk> in a human <unk> is primarily based on the sensitive data and data data in the <unk> <unk> , even though there is limited data in the <unk> <unk> .
do not <unk> the dose at this point .
2 .
<unk> <unk> <unk> ( <unk> ) <unk> <unk>
<unk> <unk> <unk> is not used immediately , the <unk> and conditions of conservation before use the liability of the <unk> <unk> and the conditions for the conservation of the <unk> and only eight hours at the time limit C or 4 hours C .
detailed information on this <unk> <unk> <unk> are available on the website of <unk> <unk> ( <unk> ) <unk> : / <unk> / <unk> <unk> <unk> <unk> .
if you inject the <unk> of these symptoms , ask your doctor .
14 <unk> <unk> was not <unk> in the <unk> of <unk> <unk> <unk> ( <unk> of <unk> <unk> ) and <unk> <unk> <unk> <unk> .
the data on <unk> <unk> <unk> are limited .
you can have one of these symptoms .
all <unk> may not be marketed .
in general , the profile of <unk> <unk> in the cases of <unk> has been <unk> to the <unk> of <unk> <unk> .
effect AND <unk> <unk> <unk>
furthermore , some patients may occur .
in such situations , the risk to treatment must be taken into consideration by the benefit of the potential and control of <unk> is premature .
<unk> may cause a <unk> of <unk> in some people affected by this virus .
<unk> , particularly <unk> , are a risk of <unk> <unk> and <unk> .
during the treatment of <unk> , the quality of <unk> <unk> is normal .
growth and development :
<unk> and contents of the <unk>
<unk> <unk> and contents of the <unk>
-
- or if it has become less effective ( or if it has become less effective ( by means of <unk> , or if it has become less effective ( through
the maximum dose <unk> is 1 200 <unk> for a day .
let us never do so , <unk> <unk> , not the <unk> , because it could <unk> the mechanism .
keep and <unk> <unk> ( 2 <unk> C - 8 <unk> C - 8 <unk> C ) .
the <unk> <unk> of <unk> <unk> in The <unk> <unk> , <unk> , <unk> and the dose , can reduce these <unk> .
the <unk> and <unk> of the <unk> are similar to those of the <unk> <unk> <unk> , mainly by a <unk> <unk> in the whole of <unk> , including <unk> <unk> , and are not linked to <unk> <unk> and <unk> .
any <unk> of <unk> <unk> of the function of <unk> in <unk> must be followed carefully and the treatment must be used if the symptoms and symptoms are used .
<unk> Special precautions for <unk>
<unk> support your body to eliminate <unk> and <unk> the <unk> paid by the <unk> .
<unk> <unk> <unk> <unk> 25 <unk> is administered <unk> .
<unk> are particularly effective for <unk> prevention and the <unk> of child <unk> and <unk> <unk> .
<unk> <unk> <unk> <unk>
<unk> <unk>
<unk> / <unk> / <unk>
<unk> , the risk of the risk of <unk> <unk> that can cause inaccurate <unk> .
<unk> data show that the treatment by <unk> <unk> may be associated with a risk of <unk> of more than <unk> <unk> .
<unk> <unk> OF <unk>
<unk> <unk> <unk> <unk> <unk> <unk> ( <unk> ) <unk> <unk> <unk>
if <unk> <unk> <unk> for more <unk> hours , it must be <unk> .
do you have <unk> <unk> <unk> with the <unk> <unk> ?
1 .
1 <unk> solution contains 100 <unk> ( <unk> <unk> ) of <unk> <unk> ( <unk> ) .
<unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>
<unk> of the system <unk> : <unk> , <unk> .
the <unk> used for medicines or products at the basic level of plants , as the <unk> or <unk> of <unk> may change the <unk> of <unk> and thereby reducing its <unk> <unk> .
as all <unk> <unk> , <unk> the treatment of <unk> in patients with the patients of the <unk> may be <unk> .
it can be necessary if patients are to be used if patients are increasing and change its usual diet .
3 .
<unk> <unk> <unk>
<unk> serious :
not <unk> .
the volume of distribution ( <unk> ) is <unk> between <unk> and <unk> <unk> .
<unk> OF <unk> <unk> <unk> <unk> <unk> <unk>
<unk> <unk> with other medicines and other forms of innovative <unk>
<unk> <unk> <unk> <unk> <unk>
3 years .
<unk> <unk> by the <unk> <unk> : the <unk> is a <unk> <unk> and must be used carefully in the event of <unk> <unk> <unk> ( see section <unk> ) .
in patients with <unk> of <unk>
moreover , a <unk> <unk> and a <unk> have been <unk> in the <unk> <unk> .
the concentration of <unk> <unk> is considerable .
<unk> The dose must be extended to 25 % - 50 % : 50 % ?
<unk> <unk> is the subject of a study which was possible to reduce the time limit .
for <unk> <unk> , an increase of 40 % of 40 % is considered as an ideal .
prevention of <unk> in the context of <unk> <unk> :
<unk> any kind of <unk> used to inform your doctor or <unk> to ensure that it is necessary .
there is a risk of vehicles and use <unk> study on the ability to drive and use <unk> <unk> .
<unk> <unk> : there are serious effects of type <unk> in the event of the <unk> .
<unk> <unk> <unk>
<unk> <unk>
information <unk> <unk> <unk>
<unk> 21 <unk>
in the studies of <unk> <unk> , there is no <unk> reaction or <unk> <unk> <unk> <unk> .
5 .
7 .
however , as at least 1 % of the dose of <unk> <unk> is <unk> in the form of <unk> , the failure is not to have a minimum effect on the elimination of <unk> ( see <unk> <unk> ) .
as all medicines , <unk> may cause side effects , but they do not occur in all patients .
<unk> <unk> is indicated in the treatment of <unk> <unk> due to sensitive <unk> in <unk> , particularly with regard to <unk> <unk> .
the treatment of treatment due to the <unk> <unk> <unk> or <unk> have been less marked in the patients of <unk> / <unk> as <unk> .
<unk> until <unk> a.m. for a week ( <unk> hours ) .
<unk> <unk> <unk> <unk> <unk> <unk>
<unk> <unk> ( glass )
<unk> and <unk> <unk> :
<unk> <unk> <unk> <unk> <unk> .
<unk> 12 .
<unk> .
<unk> OF <unk> <unk>
45 <unk> 90 <unk>
the <unk> use of <unk> is not <unk> in the course of the <unk> .
in the case of the potential risk of <unk> , the <unk> should be <unk> before the <unk> of treatment .
manufacturer <unk> <unk> <unk> <unk> <unk> <unk> <unk> , Dublin <unk>
<unk> Special precautions for storage
after a <unk> administration of <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> ( <unk> <unk> ) .
1 <unk> contains 10 <unk> equivalent to 400 <unk>
<unk> the <unk> of <unk> on <unk> and <unk> up to your next <unk> .
<unk> <unk>
<unk> in the outer <unk> <unk> <unk> , <unk> <unk> <unk> .
trials of <unk> in patients with patients with a lack of <unk> <unk> <unk> the total increase in <unk> until 100 % .
7 .
<unk> <unk> <unk>
14 .
once again , the <unk> has come to use the <unk> to <unk> .
1 .
<unk> of the application of the market and manufacturer
13 .
keep the <unk> <unk> carefully .
EU / 2 / <unk> / <unk> / <unk>
<unk> <unk>
<unk> Special warnings and precautions for use
73 % 95 %
<unk> <unk> <unk>
the evaluation assessment of these substances by the <unk> <unk> is equivalent to the average 95 of <unk> and <unk> a list of <unk> or <unk> <unk> .
1 .
<unk> ( 38 ) <unk> months ( <unk> , <unk> )
<unk> the solutions <unk> , <unk> or <unk> <unk> may be <unk> .
<unk> <unk> <unk>
if you have <unk> ideas or <unk> , delay your doctor or <unk> directly in the hospital .
<unk> <unk>
10 .
it is not the case that the <unk> will never be <unk> , even in the event of isolated symptoms , that may be <unk> <unk> , <unk> <unk> , <unk> <unk> , <unk> <unk> , <unk> <unk> , <unk> <unk> or your <unk> .
<unk> <unk> the hands carefully . <unk> , <unk> <unk> , <unk> <unk> and <unk> <unk> <unk> of the treatment of <unk> <unk> .
<unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>
in what case is <unk> used ?
name of <unk>
the treatment of <unk> in a person who has never received <unk> treatment ( <unk> <unk> <unk> ) , need to be put in place first of the <unk> and <unk> of <unk> , according to the <unk> <unk> .
<unk> the <unk> may not be marketed .
on 26 May <unk> , the <unk> has called for a group of <unk> to <unk> scientists in the short term and long term against the <unk> <unk> <unk> <unk> against <unk> <unk> .
<unk> must be taken to <unk> , 2 hours after <unk> / <unk>
<unk> <unk> <unk> concentration the end of the <unk> between two authorities .
these events may occur in a context of <unk> <unk> or <unk> , but also at the same time .
information <unk> <unk>
an in-depth analysis of people has shown that the oral <unk> of <unk> <unk> in the increase of the <unk> .
if the <unk> functions are normal , the symptoms of <unk> are somewhat <unk> .
<unk> ( <unk> <unk> ) <unk> the response of the <unk> system to facilitate the <unk> and electronic diseases .
<unk> <unk> <unk> <unk> ( <unk> and <unk> <unk> )
<unk> OF <unk> <unk> ( <unk> ) <unk> ( <unk> )
40 <unk> II II
<unk> the patients who have received an <unk> response to 90 days and which have been included in the second phase of the study , some of the patients in the second study of the study , some of the patients in <unk> and months in the long term .
<unk> <unk>
the active substance contained in <unk> , <unk> , <unk> , <unk> , <unk> of the family of the <unk> <unk> <unk> .
<unk> is usually in a centre of <unk> <unk> , although patients with <unk> <unk> 7 <unk> <unk> <unk> , <unk> <unk> <unk> , <unk> <unk> <unk> , <unk> <unk> <unk> , <unk> <unk> <unk> , <unk> <unk> .
<unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>
3 <unk>
general <unk> and administration of the <unk> administration
quantity quantity quantity volume
the role of <unk> <unk> as a factor as an integral part or <unk> cannot be excluded ( see section <unk> ) .
suspension for <unk>
<unk> <unk> : <unk> <unk> and <unk> of the <unk> code :
<unk> Special precautions for storage
<unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>
<unk> <unk> ensure that <unk> is not <unk> .
- <unk> this <unk> as well as the deliberate card , you could have the necessary deadlines .
<unk> control of the <unk> must be established .
<unk> <unk>
<unk> <unk> <unk> <unk> <unk> <unk> .
( <unk> 1 / <unk> <unk> / <unk> )
the <unk> <unk> caused by the <unk> of <unk> in <unk> , the people who have a <unk> <unk> , should prevent any contact with the product .
<unk> <unk> <unk> <unk> <unk> : + <unk> : + <unk>
a <unk> reaction may take a form of <unk> , <unk> , <unk> , <unk> , <unk> or <unk> .
<unk> <unk> <unk>
<unk> <unk> <unk>
in <unk> , 32 , 32 of <unk> ( 32 % ) who were expected to be treated in <unk> ( <unk> % ) .
during the specific analysis of the main components of the main components , there is no doubt that there is a positive trend in terms of reducing the <unk> of <unk> and a reduction of the <unk> of the <unk> have been <unk> .
in this case your doctor can bring about regular tests , particularly in order to establish the rate of <unk> in the event of the bad operation of the <unk> in case of the bad operation of the <unk> if you are <unk> or if you can be able to be <unk> .
the effects of <unk> <unk> ( such as <unk> ) have been <unk> , but most of these cases were <unk> and have not the necessary treatment .
<unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> : + 44 ( <unk> ) <unk> <unk>
children and <unk> <unk> <unk> or <unk> <unk> <unk> is against <unk> ( see condition <unk> <unk> <unk> ) .
10 minutes ) after the oral package in <unk> .
<unk> <unk> , <unk> , <unk> , <unk> ( whose <unk> and <unk> <unk> ) , <unk> <unk> ) , <unk> <unk>
they must not be allowed to <unk> or <unk> because that may be <unk> .
in a study , there is a little more <unk> study of <unk> <unk> in women .
<unk> <unk>
if you have said that you have a intolerance to some <unk> , <unk> your doctor before taking this <unk> .
in 3 days to 4 days , together with a <unk> and <unk> <unk> of <unk> of <unk> <unk> .
<unk> ( <unk> )
in the animals affected by <unk> signs , there can be more rigorous treatment .
<unk> <unk> : + 48 <unk> , <unk>
to know the conditions for the conservation of <unk> <unk> , see <unk> <unk> .
<unk> <unk>
<unk> changes :
<unk> Special warnings and precautions for use
27 September <unk> .
there is no restrictions on treatment of <unk> by <unk> during the <unk> because the <unk> does not <unk> the <unk> barrier .
<unk> % <unk> % <unk> % % of <unk> % <unk> %
a crisis <unk> with symptoms of <unk> may occur .
<unk> of the system <unk> <unk> - <unk> <unk> <unk> improved control of <unk> control may be associated with a condition condition <unk> <unk> <unk> , which is usually <unk> .
taking <unk> <unk> <unk> ( <unk> )
it is due to <unk> a <unk> of <unk> <unk> which <unk> a <unk> <unk> by genetic <unk> <unk> <unk> <unk> <unk> <unk> human <unk> .
<unk> 10 .
<unk> % ( URBAN / 93 )
<unk> , although you have just said that there is only a <unk> structure for the time being paid to the time being replaced by a new .
question No <unk> ( COS years years )
if the <unk> <unk> the area of application , there can be <unk> during a shorter period .
<unk> / <unk> / <unk> / <unk> / <unk> <unk> <unk>
<unk> <unk> :
400 units ( <unk> )
each <unk> contains 5 <unk> ( as <unk> of <unk> ) and 80 <unk> of <unk> .
23 6 .
<unk> <unk>
+ + + + + + +
after a <unk> in 1995 , the mutual recognition procedure ( <unk> decentralised <unk> <unk> ) has been better work in the year 1996 , particularly with the <unk> of the <unk> <unk> of good practice by the competent national authorities .
<unk> <unk> <unk>
subject of AIDS
the active substance contained in <unk> , <unk> , is a factor of growth which <unk> the <unk> <unk> <unk> <unk> which <unk> the <unk> <unk> and the <unk> system .
for <unk> <unk> , <unk> is usually used in combination with <unk> , but it can also be used only if the treatment is not appropriate for you .
<unk> all <unk> of <unk> <unk> , it needs to be <unk> and <unk> the <unk> of urgency ( see section <unk> ) .
<unk> the <unk> of <unk> <unk> .
we must therefore be elected .
<unk> <unk>
9 .
this <unk> must be resolved before the administration of <unk> <unk> , or the treatment must be put into close supervision .
do not take any medicines for <unk> or delay <unk> <unk> .
method AND <unk>
<unk> of <unk> 35 <unk> <unk> <unk>
<unk> and <unk> <unk> <unk> is not reflected in the children and <unk> of less than 18 years .
keep the <unk> in the outer <unk> in order to protect from light .
after all , each <unk> contains 10 <unk> of <unk> by <unk> .
oral use
the study of <unk> during <unk> or right after <unk> may reduce the symptoms of <unk> <unk> in <unk> ( see also <unk> ) .
the requirement for <unk> in the first <unk> are increasing during the first <unk> and third <unk> .
it is a condition of <unk> <unk> <unk> , which means that , for example , there is no cause of this small <unk> rate of <unk> <unk> , for example , a <unk> or <unk> treatment by means of <unk> ( <unk> , <unk> is <unk> .
the results of a study of <unk> people have shown that there have been a <unk> burden of <unk> <unk> 40 <unk> <unk> <unk> ( see part of the <unk> <unk> <unk> ( see section <unk> ) .
<unk> to prepare <unk> for <unk> <unk>
the original dose is one of two <unk> <unk> <unk> / <unk> <unk> <unk> <unk> .
<unk> in the patients of <unk> <unk> ( <unk> 1 / 10 ) :
<unk> of 1 and 5 <unk> of 5 <unk> are available .
<unk> <unk> <unk> <unk> <unk> , 2 , <unk> <unk> <unk> <unk> , Spain
<unk> <unk>
the <unk> has only been granted to its own .
<unk> October A at national level <unk> <unk>
<unk> <unk>
<unk> <unk> 1 dose under <unk>
<unk> OF <unk>
<unk> of the <unk> <unk> system : serious reactions of type <unk> , such as <unk> , <unk> of type , <unk> , <unk> , <unk> .
<unk> <unk>
<unk> of the <unk> <unk> market
keep the <unk> in the outer <unk> .
mentioned in this <unk> , talk about your doctor or <unk> .
<unk> OF <unk>
30 million 30 million 30 million 30
<unk> OF <unk>
in the absence of <unk> studies , this <unk> must not be <unk> with other medicines .
<unk> <unk>
<unk> <unk> <unk> the <unk> in <unk> <unk> by a <unk> , the product may be <unk> during 28 days .
<unk> ( <unk> 1 / <unk> / <unk> )
without <unk> .
<unk> of any type of kind in the Euratom procedure ( <unk> / 99 )
<unk> is very <unk> and its <unk> are mainly in the <unk> .
<unk> <unk>
list OF <unk>
food and <unk> may take part in the course of or outside <unk> .
<unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>
<unk> <unk>
<unk> <unk> <unk>
tests to verify the requirements are of <unk> , stability ( <unk> of reference ) and the precision of the measures .
<unk> <unk> of <unk> <unk> have been <unk> in the light of <unk> <unk> <unk> after <unk> administration and <unk> .
the treatment of the <unk> <unk> has led to a significant increase in <unk> activities in the <unk> .
<unk> <unk> <unk> by the <unk> .
the Committee on <unk> <unk> for Human <unk> ( <unk> ) granted that the benefits of <unk> <unk> are higher than the risks of treatment of <unk> <unk> <unk> <unk> .
there is a <unk> when the rate of <unk> is too low .
2 .
12 / 11 / <unk> in 1996 / <unk> :
the <unk> which <unk> the <unk> must be <unk> with a <unk> <unk> that <unk> is <unk> .
suspension for a or four <unk> <unk> <unk> of 500 <unk> <unk> <unk> ( 1.4 <unk> / <unk> ) .
<unk> <unk> <unk>
via <unk> <unk> , 37 <unk> <unk>
<unk> <unk> <unk> :
this difference is not considered as wide as <unk> <unk> .
5 .
<unk> is the production of <unk> <unk> which <unk> the <unk> bodies .
<unk> <unk> <unk>
<unk> :
3 .
in <unk> <unk> , more than 90 % of patients have been <unk> in these <unk> , with a period of <unk> of 2 days .
<unk> 16 .
<unk> read the <unk> carefully before using this <unk> .
not applicable provisions
<unk> <unk> / <unk> <unk> <unk> ( <unk> of 3 months ) <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>
<unk> <unk> <unk> ( <unk> and <unk> )
<unk> :
the administration of treatment must begin so as to ensure that <unk> is <unk> or confirmed .
5 .
<unk> <unk>
no precautions for storage .
the <unk> analysis defined in a <unk> <unk> <unk> has not led to a significant <unk> difference on the <unk> criterion of <unk> <unk> next week .
.
<unk> Special precautions for disposal and other handling
<unk> <unk> Agency
11 .
<unk> <unk> of <unk> <unk> the <unk> directly at the <unk> of <unk> <unk> on the website of <unk> <unk> , regardless of the <unk> <unk> .
solution AND <unk>
these instructions <unk> the first stages :
for any additional information with regard to <unk> , <unk> contact with the local representative of the <unk> of <unk> <unk> .
in the event of <unk> of <unk> , patients must be informed on signs and symptoms of a <unk> <unk> and the symptoms of the <unk> .
<unk> <unk>
<unk> is usually under way of <unk> <unk> by a doctor or <unk> .
studies from <unk> <unk> after <unk> <unk> have shown that the effects of <unk> are mainly <unk> at the level of <unk> and the <unk> <unk> system , probably by <unk> <unk> .
<unk> reactions ( <unk> 1 / <unk> ) , related to the treatment by <unk> <unk> , <unk> , <unk> , <unk> , <unk> or reaction to the <unk> <unk> may occur .
if you are <unk> to take <unk> <unk> , you have forgotten that you do not take it later in the day .
<unk> <unk> their advice .
<unk> <unk> <unk> <unk> <unk>
for a period of <unk> <unk> <unk> <unk> 6 <unk> / <unk>
28 % / 36
<unk> <unk> are a <unk> effect of the treatment of <unk> <unk> and <unk> .
5 .
<unk> <unk>
it is only a question of veterinary provisions .
<unk> <unk> <unk> the Treaties by <unk> or any other <unk> of any kind of kind or through <unk> <unk> , the treatment of <unk> <unk> may occur with the risk of <unk> <unk> .
<unk> Special precautions for disposal and other handling
54 A .
the <unk> <unk> is less than the <unk> at the same time .
16 .
they will only apply only to the species for which there is no critical concentration in the case of the kind of critical concentration of the kind of <unk> <unk> <unk> <unk> .
in particular , tell your doctor if you inject medicines any active substance :
if you inject the <unk> of <unk> and <unk> around the <unk> , <unk> <unk> or <unk> , immediately <unk> your doctor .
consequently , no progress has been available in the patients of a bad failure .
<unk> <unk>
<unk> <unk> <unk>
<unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>
no adjustment is required in the <unk> case .
as all <unk> <unk> , <unk> the treatment of <unk> in patients with the patients of the <unk> may be <unk> .
in <unk> <unk> , who <unk> <unk> , no person has developed <unk> <unk> against the <unk> after a single use or use of the limited use of 27 patients .
0 ( <unk> % )
it has not been found of <unk> <unk> <unk> of <unk> between the elderly <unk> and <unk> issues .
dose <unk>
<unk> <unk> <unk> <unk> <unk> .
in the <unk> traffic , the <unk> has a few minutes .
<unk> B :
<unk> <unk> with a level of <unk> at the <unk> week <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> .
- a <unk> of 30 <unk> more than 30 <unk> <unk> or <unk> <unk>
<unk> <unk> <unk>
June <unk>
<unk> <unk> <unk> ( <unk> )
<unk> <unk> <unk> <unk> <unk> :
13 13 13 13 13 13 13
<unk> <unk> <unk>
oral use
<unk> <unk> the <unk> and use pressure on the <unk> for some seconds .
<unk> <unk> <unk> <unk> <unk> <unk> .
9 .
Luxembourg / <unk> <unk> <unk> / <unk> <unk> <unk> / <unk> : + 32 ( 0 ) 2 <unk>
<unk> <unk>
<unk> <unk> <unk>
<unk> ( whose <unk> , <unk> , <unk> ) <unk> <unk> :
<unk> <unk>
if the <unk> at <unk> is <unk> or does not work properly ( <unk> <unk> ) , it must be <unk> and a new <unk> to <unk> must be <unk> .
a <unk> use of <unk> <unk> ( not more than 1 <unk> on a period of 24 hours ) usually , but the use of other circumstances must be dealt with by your doctor .
there is no mention of <unk> <unk> that <unk> the <unk> function related to <unk> <unk> , the ability to eliminate the <unk> may be reduced in the poor issues .
<unk> the <unk> of <unk> <unk> <unk> , and <unk> the lack of <unk> of air <unk> into the skin .
for the more <unk> information , see <unk> <unk> .
<unk> B :
do not <unk> this <unk> .
<unk> <unk>
the active <unk> , a <unk> <unk> , is <unk> by <unk> <unk> in <unk> <unk> .
these adverse effects are : <unk> , <unk> of <unk> , <unk> <unk> , <unk> <unk> , <unk> <unk> , <unk> <unk> , <unk> <unk> , <unk> <unk> , <unk> <unk> , <unk> <unk> , <unk> <unk> , <unk> <unk> <unk> <unk> ( <unk> <unk> ) .
if you inject <unk> <unk> <unk> you inject your dose at time , then you will be able to take your <unk> .
in cases where a <unk> has been <unk> ( <unk> of <unk> <unk> , <unk> or <unk> ) , the treatment of <unk> must be used .
list OF <unk>
b .
the measures to take part in the past have been <unk> since the <unk> and <unk> of the symptoms .
<unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> , <unk> 10 <unk> <unk> , <unk> 10 <unk> <unk> , <unk> 10 <unk> <unk> , <unk> 10
women women women women women women women
<unk> <unk>
do not <unk> the <unk> <unk>
48 weeks weeks
<unk> <unk> <unk>
the volume of distribution at the <unk> balance ( <unk> ) is to be <unk> around .
this <unk> may lead to the increase of the <unk> rate of products such as <unk> , <unk> and <unk> which are <unk> by the <unk> <unk> .
<unk> of <unk>
<unk> and <unk> :
<unk> <unk>
in <unk> a study of <unk> <unk> ( <unk> ) , the association of 300 <unk> <unk> <unk> and <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> ( <unk> / <unk> ) , <unk> <unk> <unk> <unk> <unk> ( <unk> / 2000 ) , <unk> <unk> .
important differences had been identified in the lack of adequate evidence of <unk> <unk> and effective efficiency , <unk> <unk> <unk> <unk> by the use of <unk> <unk> and the <unk> of a positive report .
a <unk> <unk> contains a high amount of <unk> <unk> for 80 <unk> in <unk> <unk> <unk> after the recommendations .
Netherlands Netherlands
this product <unk> must not be used in <unk> because the <unk> regulations are different .
it is therefore <unk> to reduce the treatment ( see section <unk> ) .
no specific <unk> has been <unk> in the event of <unk> administration ( 20 <unk> ) with <unk> ( 25 <unk> ) , and with <unk> ( <unk> <unk> ) .
<unk> containing the <unk> solution .
as in the <unk> <unk> , children and <unk> have also led to other <unk> effects of <unk> ( such as <unk> , instability and <unk> ) ( see <unk> <unk> ) .
<unk> <unk> <unk> A / <unk> <unk>
<unk> : + 46 8 <unk> <unk>
the content of the <unk> :
there is a need to <unk> the treatment in patients with <unk> <unk> <unk> <unk> <unk> .
in each <unk> group , the adverse effects have been presented on a <unk> agenda .
25 % 27 % 25 %
13 / 20 <unk> / <unk> <unk> <unk> <unk> <unk> <unk> <unk>
<unk> <unk> <unk> <unk> to prepare <unk> <unk>
<unk> : increase <unk> rates of <unk> , increase <unk> and <unk> <unk> .
for patients with a further <unk> of their symptoms , the dose may be extended , the dose may be extended to all on 4 days , <unk> <unk> <unk> <unk> <unk> ( <unk> <unk> <unk> ) ( as shown in the <unk> ) ) .
contents OF <unk> <unk> , <unk> <unk> <unk>
name of <unk>
- <unk> <unk> ( also <unk> ) , <unk> <unk> )
<unk> <unk> 2006
<unk> of <unk> , 40 <unk> Madrid <unk> :
23 <unk> III
in <unk> <unk> and for the use of the market for the market , the link in the population of the people of patients and <unk> .
each <unk> contains <unk> <unk> or 4 <unk> <unk> .
1 1 .
<unk> treatment and treatment of <unk> will need to be <unk> .
the active substance is <unk> <unk> .
<unk> <unk>
<unk> <unk> <unk>
<unk> studies have been carried out in <unk> ?
